Compare PLSE & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | ABCL |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.1B |
| IPO Year | 2015 | 2020 |
| Metric | PLSE | ABCL |
|---|---|---|
| Price | $47.55 | $12.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $60.67 | $16.82 |
| AVG Volume (30 Days) | 419.0K | ★ 4.7M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $480.71 | N/A |
| Revenue Next Year | $177.98 | $7.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $12.56 | $2.75 |
| 52 Week High | $58.90 | $14.98 |
| Indicator | PLSE | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 45.97 |
| Support Level | $24.27 | $11.78 |
| Resistance Level | $55.36 | $12.88 |
| Average True Range (ATR) | 3.15 | 0.75 |
| MACD | -0.78 | -0.26 |
| Stochastic Oscillator | 31.05 | 8.65 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.